[go: up one dir, main page]

AU5081200A - Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia - Google Patents

Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia

Info

Publication number
AU5081200A
AU5081200A AU50812/00A AU5081200A AU5081200A AU 5081200 A AU5081200 A AU 5081200A AU 50812/00 A AU50812/00 A AU 50812/00A AU 5081200 A AU5081200 A AU 5081200A AU 5081200 A AU5081200 A AU 5081200A
Authority
AU
Australia
Prior art keywords
inducible
preventing
antisense oligonucleotides
cerebral ischemia
treating cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50812/00A
Inventor
Andrees Bohme
Sophie Parmentier
Michel Plotkine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9905629A external-priority patent/FR2793142A1/en
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU5081200A publication Critical patent/AU5081200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU50812/00A 1999-05-04 2000-05-03 Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia Abandoned AU5081200A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9905629 1999-05-04
FR9905629A FR2793142A1 (en) 1999-05-04 1999-05-04 Antisense oligonucleotides of an inductible isoform of nitrogen monoxide synthase, used to treat cerebral ischemia
US13973599P 1999-06-18 1999-06-18
US60139735 1999-06-18
PCT/FR2000/001191 WO2000066725A1 (en) 1999-05-04 2000-05-03 Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia

Publications (1)

Publication Number Publication Date
AU5081200A true AU5081200A (en) 2000-11-17

Family

ID=26234944

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50812/00A Abandoned AU5081200A (en) 1999-05-04 2000-05-03 Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia

Country Status (2)

Country Link
AU (1) AU5081200A (en)
WO (1) WO2000066725A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001229501A1 (en) * 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
JP7547201B2 (en) 2018-01-12 2024-09-09 ブリストル－マイヤーズ スクイブ カンパニー Antisense oligonucleotides targeting alpha-synuclein and uses thereof - Patents.com
MY203356A (en) 2018-01-12 2024-06-25 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306386D0 (en) * 1993-03-26 1993-05-19 Wellcome Found Gene expression
FR2722507B1 (en) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa ADENOVIRUS COMPRISING A GENE ENCODING NO SYNTHASE

Also Published As

Publication number Publication date
WO2000066725A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
IL149694A0 (en) Therapeutic uses of lna-modified oligonucleotides
HUP0105154A3 (en) Use of anticonvulsant derivatives for treating cluster headaches
EP0975649A4 (en) RNASE L ACTIVATORS AND ANTISENSE OLIGONUCLEOTIDES THAT CAN EFFECTIVELY TREAT MALIGNANT CONDITIONS EXPRESSING TELOMERASE
HUP0202853A3 (en) Use of retigabin for treating neuropathic pain
AU3811897A (en) Antisense oligonucleotides as antibacterial agents
AU4200400A (en) Antisense oligonucleotide modulation of stat3 expression
AU6296199A (en) Antisense modulation of smad1 expression
IL150304A0 (en) Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
AU2666797A (en) Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
AU2001279709A1 (en) Pyrimidine derivatives and their use for preventing and treating cerebral ischaemia
AU8327798A (en) Antisense oligonucleotide sequences as inhibitors of microorganisms
AU2433800A (en) Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
AU1686997A (en) Modified vegf antisense oligonucleotides for treatment of skin disorders
AU2512501A (en) Use of trimebutine for treating pain
AU1156699A (en) Antisense oligonucleotides against tenascin for treating vitiligo
AU5081200A (en) Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia
PL346162A1 (en) Antisense oligonucleotides for the inhibition of vegf expression
WO2000001393A8 (en) OLIGONUCLEOTIDE INHIBITORS OF bcl-xL
AU6459199A (en) Antisense oligonucleotides which inhibit telomerase's activity and their uses
AU2585197A (en) Antisense approach to gene inhibition
AU1249299A (en) Chimeric antisense oligonucleotides against tnf-alpha and their uses
AU5093899A (en) Antisense oligonucleotides targeted to il-15
IL143304A0 (en) The use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
IL149533A0 (en) Treatment of sle with dehydropiandrosterone
AU6920898A (en) Antisense inhibition of human stat-6

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase